Enhanced Nitric Oxide-Releasing Materials

增强一氧化氮释放材料

• 批准号: 6790749
• 负责人: Scott I Merz
• 金额: $ 53.68万
• 依托单位: MC3, INC.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-04-01 至 2006-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6790749
• 关键词: bioengineering /biomedical engineering; biomaterial compatibility; biomaterial development /preparation; biotechnology; cardiovascular prosthesis; cell adhesion; circulatory assist; medical implant science; nitric oxide; platelet activation; polymers; reducing agents; sheep; surface coating

DESCRIPTION (provided by applicant): The goal of this project is to develop a family of nitric oxide-releasing materials (NORM), formed by adding nitric oxide (NO) donor compounds to polymers. The enhanced NORM developed in Phase I of this effort released NO for a prolonged period of time, at rates exceeding the release of the normal endothelium. The NO donor formulations from Phase I will be combined with commercially-available biopolymers. The resulting NORM will be used to treat prosthetic vascular grafts, which will be tested in long-term implantation experiments in sheep to evaluate the efficacy of the materials in prolonging patency. The goal of the project is to focus on developing a prosthetic vascular graft with improved long-term patency as a commercial application of NORM. The advances in NORM technology achieved in pursuit of this goal is expected to lead to other applications of this technology. If successful, NORM technology has the potential to contribute substantially to the field of prosthetic vascular grafts. The number of grafts implanted for hemodialysis access alone is a sizeable and growing market. Failure rates with prosthetic grafts are approximately 40% after one year for lower extremity bypass and hemodialysis grafts. Early thrombosis is common, as is long-term failure due to intimal hyperplasia. Nitric oxide released from NORM may potentially contribute to preventing short- and long-term failure modes. A pilot study showed promising results for short-term benefits.

描述（由申请人提供）： 该项目的目的是开发一种一氧化氮释放材料（NORM），该家族是通过向聚合物添加一氧化氮（NO）供体化合物而形成的。在这项工作的第一阶段发展的增强规范延长了NO，其速度超过了正常内皮的释放速度。 I期的NO供体配方将与商业上可用的生物聚合物结合使用。所得的规范将用于治疗假体血管移植物，将在长期植入实验中对其进行测试，以评估材料在延长通畅方面的功效。该项目的目的是专注于开发一种假肢血管移植，并改善了长期通畅作为规范的商业应用。预计追求这一目标的规范技术的进步将导致该技术的其他应用。 如果成功的话，Norm Technology有可能为假肢血管移植物的领域做出基本贡献。仅植入血液透析的移植物数量是一个庞大而增长的市场。下肢和血液透析移植物一年后，假肢移植物的失败率约为40％。早期血栓形成很常见，由于内膜增生而导致长期失败。从Norm释放的一氧化氮可能有助于预防短期和长期失败模式。一项试点研究显示了短期收益的有希望的结果。